Skip to content
PubMed This is a summary of 8 peer-reviewed journal articles Updated
Pediatric Neurology

Symptoms, Seizures, and Brain Development

At a Glance

SLC35A2-CDG can cause variable neurological symptoms, including infantile spasms or other seizures, developmental delay, low muscle tone, movement difficulties, and cortical visual impairment. EEG and MRI findings help guide care, but MRI alone cannot predict a child’s future development.

Because SLC35A2-CDG primarily affects the brain, the symptoms are mostly neurological. While the diagnosis can be frightening, it is important to know that the severity of these symptoms can vary significantly from one child to another [1][2].

Understanding the “Encephalopathy” Pattern

Many children with this condition present with what doctors call Developmental and Epileptic Encephalopathy (DEE). This means that developmental impairment arises from both the underlying genetic neurodevelopmental disorder and the disruptive electrical activity from seizures [3][4]. Developmental delay can occur before seizures begin, or persist despite seizure control.

The most common way this starts is through infantile spasms (also called West Syndrome). These are not typical “shaking” seizures; instead, they often look like sudden, brief clusters of head drops or the body “scrunching” forward [3]. When a child has these spasms, their EEG (a test that measures brain waves) often shows a chaotic, high-voltage pattern called hypsarrhythmia [4]. Suspected infantile spasms require urgent neurologic assessment even when individual events are brief. If left untreated, this chaotic brain activity can significantly slow down or even “pause” a child’s development.

Seizure Variability

While epilepsy is frequent in reported cohorts, the experience is not the same for everyone:

  • Early Encephalopathy: Some infants start having spasms very early, often leading to more significant intellectual challenges [1].
  • Focal Epilepsy: Other children may have seizures that come from one specific spot in the brain [1].
  • Seizure-Free Cases: There are reported cases of children with SLC35A2-CDG who have never had a seizure at all, or who have only minor neurological symptoms [5][2].

Seizures in this condition can sometimes be drug-resistant, meaning they don’t respond well to standard medications. Some doctors have found success using hormonal treatments like ACTH, though the benefit may sometimes be temporary [4][6].

Developmental Milestones and Muscle Tone

Many children with SLC35A2-CDG experience some level of Global Developmental Delay (GDD), which affects physical movement, speech, and social interaction [3].

  • Hypotonia: This is the medical term for low muscle tone. You might notice your child feels “floppy” or has difficulty holding their head up or sitting without support [3].
  • Motor Skills: Many children face significant challenges with mobility. In some studies, many children remained “nonambulatory” (meaning they did not learn to walk on their own), while others developed spasticity (stiffness) in their legs [3][7].
  • Vision: Some children have cortical visual impairment (CVI), where the eyes are healthy but the brain has trouble processing what it sees [7].

What the Brain MRI Shows

When doctors look at a brain MRI of a child with SLC35A2-CDG, they often see variable signs that can point to the diagnosis, though MRI alone cannot confirm or predict long-term outcomes:

  • Delayed Myelination: Myelin is the protective coating around nerve fibers (like insulation on a wire). In this condition, the brain may be slow to develop this coating, which slows down the signals sent between brain cells [3].
  • Thin Corpus Callosum: The corpus callosum is the bridge that allows the left and right sides of the brain to talk to each other. In many patients, this bridge is smaller or thinner than usual [3][8].
  • Cerebral Atrophy: This refers to a slight shrinking or “thinning” of the brain tissue. While it is reported, it is not always progressive [3][7].
  • White Matter Abnormalities: Doctors may see patchy “bright spots” in the white matter of the brain, which usually stay stable over time rather than getting worse [3].

Understanding these findings helps your care team tailor therapies—such as physical, occupational, and speech therapy—to your child’s specific needs.

Common questions in this guide

What do infantile spasms look like in a child with SLC35A2-CDG?
Infantile spasms are often brief, repeated clusters of head drops or a sudden forward “scrunching” of the body rather than ordinary shaking. They may happen when a child is waking or falling asleep. Suspected spasms need urgent neurologic assessment because untreated abnormal brain activity can interfere with development.
Does every child with SLC35A2-CDG develop epilepsy?
No. Seizures are common in reported children, but some have infantile spasms, some have seizures arising from one area of the brain, and some never have seizures or have only mild neurological symptoms. The type and severity of epilepsy can vary substantially.
What does developmental and epileptic encephalopathy mean in SLC35A2-CDG?
It means that developmental difficulties may result from both the underlying genetic brain condition and the effects of ongoing seizure activity. Developmental delay can begin before seizures or continue even after seizures are controlled.
What might a brain MRI show in SLC35A2-CDG?
An MRI may show delayed development of myelin, a thin corpus callosum, some thinning of brain tissue, or white matter changes. These findings can vary and may remain stable; an MRI alone cannot confirm the diagnosis or predict a child’s long-term development.
How can SLC35A2-CDG affect movement and vision?
Children may have global developmental delay, low muscle tone, difficulty sitting or walking, or stiffness in the legs. Some also have cortical visual impairment, in which the eyes may be healthy but the brain has difficulty processing visual information. Physical, occupational, and speech therapies can be tailored to the child’s needs.
What treatments may be considered when seizures do not respond to medicine?
A neurologist may adjust anti-seizure medicines and may consider treatments such as adrenocorticotropic hormone, also called ACTH, for some children with difficult-to-control seizures. ACTH can help in some cases, but the benefit may be temporary. Treatment choices should be individualized by the child’s neurology team.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on SLC35A2-CDG.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific type of seizures is my child having, and does the EEG show hypsarrhythmia?
  2. 2.How do the white matter findings or the size of the corpus callosum on the MRI help explain my child's current motor delays?
  3. 3.Given the risk of drug-resistant epilepsy, are there specific medications like ACTH or dietary therapies we should consider early on?
  4. 4.Is my child's developmental profile more consistent with a focal epilepsy or a more generalized encephalopathy?
  5. 5.What is the long-term outlook for children with this specific MRI pattern regarding their ability to walk or communicate?

References

References (8)
  1. 1

    Clinical Features, Neuropathology, and Surgical Outcome in Patients With Refractory Epilepsy and Brain Somatic Variants in the SLC35A2 Gene.

    Barba C, Blumcke I, Winawer MR, et al.

    Neurology 2023; (100(5)):e528-e542 doi:10.1212/WNL.0000000000201471.

    PMID: 36307217
  2. 2

    SLC35A2-CDG: Novel variant and review.

    Quelhas D, Correia J, Jaeken J, et al.

    Molecular genetics and metabolism reports 2021; (26()):100717 doi:10.1016/j.ymgmr.2021.100717.

    PMID: 33552911
  3. 3

    Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients.

    Vals MA, Ashikov A, Ilves P, et al.

    Journal of inherited metabolic disease 2019; (42(3)):553-564 doi:10.1002/jimd.12055.

    PMID: 30746764
  4. 4

    SLC35A2-related congenital disorder of glycosylation: Defining the phenotype.

    Yates TM, Suri M, Desurkar A, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2018; (22(6)):1095-1102 doi:10.1016/j.ejpn.2018.08.002.

    PMID: 30194038
  5. 5

    Mosaicism of the UDP-Galactose transporter SLC35A2 in a female causing a congenital disorder of glycosylation: a case report.

    Westenfield K, Sarafoglou K, Speltz LC, et al.

    BMC medical genetics 2018; (19(1)):100 doi:10.1186/s12881-018-0617-6.

    PMID: 29907092
  6. 6

    Four New Cases of SLC35A2-CDG With Novel Mutations and Clinical Features.

    Abuduxikuer K, Wang JS

    Frontiers in genetics 2021; (12()):658786 doi:10.3389/fgene.2021.658786.

    PMID: 34122512
  7. 7

    A case of de novo splice site variant in SLC35A2 showing developmental delays, spastic paraplegia, and delayed myelination.

    Miyamoto S, Nakashima M, Ohashi T, et al.

    Molecular genetics & genomic medicine 2019; (7(8)):e814 doi:10.1002/mgg3.814.

    PMID: 31231989
  8. 8

    A case of early onset epileptic encephalopathy with de novo mutation in SLC35A2: Clinical features and treatment for epilepsy.

    Kimizu T, Takahashi Y, Oboshi T, et al.

    Brain & development 2017; (39(3)):256-260 doi:10.1016/j.braindev.2016.09.009.

    PMID: 27743886

This page is for informational purposes only and does not constitute medical advice. It explains symptoms, seizures, and brain MRI findings in SLC35A2-CDG, but your child’s neurologist and care team should guide urgent evaluation and treatment decisions.